Amundi Pioneer Asset Management Inc. Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Amundi Pioneer Asset Management Inc. raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 43.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,157,567 shares of the biopharmaceutical company’s stock after buying an additional 1,858,416 shares during the quarter. Amundi Pioneer Asset Management Inc.’s holdings in Gilead Sciences were worth $358,717,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Dodge & Cox grew its holdings in Gilead Sciences by 35.7% during the 4th quarter. Dodge & Cox now owns 17,107,888 shares of the biopharmaceutical company’s stock valued at $996,706,000 after buying an additional 4,500,035 shares in the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $767,548,000. UBS Asset Management Americas Inc. boosted its position in shares of Gilead Sciences by 4.6% during the 4th quarter. UBS Asset Management Americas Inc. now owns 8,997,053 shares of the biopharmaceutical company’s stock valued at $524,168,000 after acquiring an additional 392,859 shares during the last quarter. Morgan Stanley boosted its position in shares of Gilead Sciences by 18.4% during the 4th quarter. Morgan Stanley now owns 7,124,342 shares of the biopharmaceutical company’s stock valued at $415,063,000 after acquiring an additional 1,106,826 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Gilead Sciences by 0.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 6,534,485 shares of the biopharmaceutical company’s stock valued at $380,700,000 after acquiring an additional 18,926 shares during the last quarter. 76.36% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Brett A. Pletcher sold 1,486 shares of the business’s stock in a transaction dated Thursday, March 11th. The shares were sold at an average price of $63.36, for a total transaction of $94,152.96. Following the transaction, the executive vice president now owns 29,166 shares in the company, valued at $1,847,957.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Brett A. Pletcher sold 1,975 shares of the business’s stock in a transaction dated Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total transaction of $133,134.75. Following the transaction, the executive vice president now owns 28,832 shares in the company, valued at approximately $1,943,565.12. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.

NASDAQ GILD opened at $65.60 on Thursday. Gilead Sciences, Inc. has a 1-year low of $56.56 and a 1-year high of $85.79. The company has a current ratio of 3.25, a quick ratio of 3.15 and a debt-to-equity ratio of 1.65. The stock has a 50-day moving average of $64.21 and a 200-day moving average of $62.46. The firm has a market cap of $82.59 billion, a PE ratio of 67.63, a price-to-earnings-growth ratio of 0.67 and a beta of 0.51.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, February 4th. The biopharmaceutical company reported $2.19 EPS for the quarter, beating analysts’ consensus estimates of $2.15 by $0.04. The business had revenue of $7.42 billion during the quarter, compared to analyst estimates of $7.11 billion. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.06 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 30th. Shareholders of record on Monday, March 15th were given a dividend of $0.71 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.68. The ex-dividend date of this dividend was Friday, March 12th. This represents a $2.84 dividend on an annualized basis and a yield of 4.33%. Gilead Sciences’s dividend payout ratio is presently 46.25%.

A number of brokerages have recently issued reports on GILD. TheStreet upgraded Gilead Sciences from a “c” rating to a “b-” rating in a research report on Tuesday, March 30th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell dropped their price target on Gilead Sciences from $75.00 to $72.00 in a research report on Tuesday, December 22nd. Guggenheim upgraded Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Monday, January 4th. Credit Suisse Group lifted their price target on Gilead Sciences from $65.00 to $66.00 and gave the company a “neutral” rating in a research report on Friday, February 5th. Finally, Robert W. Baird lifted their price target on Gilead Sciences from $63.00 to $67.00 and gave the company a “neutral” rating in a research report on Wednesday, December 16th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $96.04.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading: VIX – Volatility Index

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.